XML 45 R32.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Segments of Business (Tables) | 3 Months Ended
--- | ---
Jun. 30, 2024
Segment Reporting [Abstract] |
Schedule of Financial Information Relating to Reportable Operating Segments and Reconciliations to the Condensed Consolidated Totals | Financial information relating to the Company’s reportable operating segments and reconciliations to the condensed consolidated totals was as follows:
| Three Months Ended June 30, |  |
(In millions) | 2024 |  | 2023 |  |  |  |
Segment revenues (1) |  |  |  |  |  |  |
U.S. Pharmaceutical | $ | 71,715 |  |  | $ | 67,160 |  |  |  |  |
Prescription Technology Solutions | 1,241 |  |  | 1,244 |  |  |  |  |
Medical-Surgical Solutions | 2,636 |  |  | 2,611 |  |  |  |  |
International | 3,691 |  |  | 3,468 |  |  |  |  |
Total revenues | $ | 79,283 |  |  | $ | 74,483 |  |  |  |  |
Segment operating profit (2) |  |  |  |  |  |  |
U.S. Pharmaceutical (3) | $ | 781 |  |  | $ | 827 |  |  |  |  |
Prescription Technology Solutions (4) | 203 |  |  | 231 |  |  |  |  |
Medical-Surgical Solutions | 188 |  |  | 227 |  |  |  |  |
International | 90 |  |  | 57 |  |  |  |  |
Subtotal | 1,262 |  |  | 1,342 |  |  |  |  |
Corporate expenses, net (5) | (103) |  |  | (204) |  |  |  |  |
Interest expense | (75) |  |  | (47) |  |  |  |  |
Income before income taxes | $ | 1,084 |  |  | $ | 1,091 |  |  |  |  |
(1)Revenues from services on a disaggregated basis represent approximately 1% of the U.S. Pharmaceutical segment’s total revenues, less than 39% of the RxTS segment’s total revenues, less than 1% of the Medical-Surgical Solutions segment’s total revenues, and less than 1% of the International segment’s total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S. (2)Segment operating profit includes gross profit, net of total operating expenses, as well as other income, net, for the Company’s reportable segments. (3)The Company’s U.S. Pharmaceutical segment’s operating profit includes the following: •cash receipts for the Company’s share of antitrust legal settlements of $90 million and $118 million for the three months ended June 30, 2024 and 2023, respectively. These gains were recorded within “Cost of sales” in the Company’s Condensed Consolidated Statements of Operations; •a charge of $57 million for the three months ended June 30, 2024 related to the estimated liability for opioid-related claims, as discussed in more detail in Financial Note 9, “Commitments and Contingent Liabilities;" •a loss of $43 million for the three months ended June 30, 2024 related to one of the Company’s equity method investments, which was recorded within “Other income, net” in the Company’s Condensed Consolidated Statement of Operations; and •a credit of $2 million and a charge of $32 million related to the last-in, first-out method of accounting for inventories for the three months ended June 30, 2024 and 2023, respectively. These amounts were recorded within “Cost of sales” in the Company’s Condensed Consolidated Statements of Operations. (4)The Company’s RxTS segment’s operating profit for the three months ended June 30, 2023 includes a gain of $28 million resulting from a fair value adjustment of the Company’s contingent consideration liability related to the acquisition of Rx Savings Solutions, LLC completed in November 2022. (5)Corporate expenses, net includes the following: •a net gain of $110 million for the three months ended June 30, 2024 related to the Company’s investments in equity securities of certain U.S. growth stage companies in the healthcare industry, as discussed in more detail in Financial Note 8, “Fair Value Measurements;” •a net charge of $55 million for the three months ended June 30, 2024 related to the estimated liability for opioid-related claims, as discussed in more detail in Financial Note 9, “Commitments and Contingent Liabilities;" and •restructuring charges of $40 million for the three months ended June 30, 2023 for restructuring initiatives as discussed in more detail in Financial Note 2, “Restructuring, Impairment, and Related Charges, Net.”

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration